Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Stauffer, Virginia L ^a   Sniadecki, Jennifer L ^a   Piezer, Kevin W ^a   Gatz, Jennifer ^a   Kollack Walker, Sara ^a   Hoffmann, Vicki P ^a   Conley, Robert ^a   Durell, Todd ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AKATHESIA; ANXIETY; APPETITE; ARTICLE; ATTENTION DISTURBANCE; BODY MASS; CHILL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CYST; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; NEOPHARYNGITIS; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT; XEROSTOMIA; AFRICAN AMERICAN; CAUCASIAN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG TOXICITY; META ANALYSIS; OBESITY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG TOXICITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; OBESITY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 78049337441     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-89     Document Type: Article

References (42)

1. Robins LN, Reiger D. Psychiatric Disorders of America: the Epidemiologic Catchment Area study. 1991, The Free Press, New York, New York.
2. Boydell J, van Os J, McKenzie K, Allardyce J, Goel R, McCreadie RG, Murray RM. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with the environment. BMJ 2001, 323:1336-1338. 10.1136/bmj.323.7325.1336, 60671, 11739218.
3. Brekke, John S, Prindle C, Bae SW, Long JD. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 2001, 52:1358-1366. 10.1176/appi.ps.52.10.1358, 11585953.
4. Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M. Racial differences in the diagnosis of psychosis. Schizophr Res 1996, 21:117-124. 10.1016/0920-9964(96)00041-2, 8873779.
5. Adebimpe VR. Overview: American blacks and psychiatry. Transcultural Psychiatry Research Review 1984, 21:83-111.
6. Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, Snowden LR. Variations in the use of second-generation antipsychotics mediation by race among adult psychiatric patients. Psychiatr Serv 2004, 55:677-684. 10.1176/appi.ps.55.6.677, 15175466.
7. Mallinger JB, Fisher SG, Brown T, Lamberti JS. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006, 57:133-136. 10.1176/appi.ps.57.1.133, 16399976.
8. Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res 2004, 66:169-175. 10.1016/S0920-9964(03)00102-6, 15061250.
9. Mark TL, Palmer LA, Russo PA, Vasey J. Examination of treatment patterns by race. Ment Health Serv Res 2003, 5:241-250. 10.1023/A:1026281118990, 14672502.
10. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Amer J Psychiatry 2002, 159:567-572.
11. Van Dorn RA, Swanson JW, Swartz MS, Elbogen EB. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Ment Health Serv Res 2005, 7:123-134. 10.1007/s11020-005-3783-z, 15974158.
12. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004, 55:151-156. 10.1176/appi.ps.55.2.151, 14762239.
13. Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003, 160:1817-1822. 10.1176/appi.ajp.160.10.1817, 14514496.
14. Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ. Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. J Clin Psychiatry 2003, 64:635-639. 10.4088/JCP.v64n0603, 12823076.
15. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother 2003, 37:625-30. 10.1345/aph.1C321, 12708934.
16. Aliyu M, Calkins ME, Swanson CL, Lyons PD, Savage RM, May R, Wiener H, McLeod-Bryant S, Nimgaonkar VL, Ragland JD, Gur RE, Gur RC, Bradford LD, Edwards N, Kwentus J, McEvoy JP, Santos AB, McCleod-Bryant S, Tennison C, Go RC, Allen TB, . PAARTNERS Study Group Project among African Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr Res 2006, 87:32-44. 10.1016/j.schres.2006.06.027, 16887335, PAARTNERS Study Group.
17. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A. A 28-week randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:572-581. 10.4088/JCP.08m04421, 19323965.
18. Kinon BJ, Lipkovich I, Edwards SE, Adams DH, Ascher-Svanum H, Siris SG. A 24- week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia and schizoaffective disorder with prominent depressive symptoms. J Clin Psychopharmacol 2006, 26:157-162. 10.1097/01.jcp.0000204137.82298.06, 16633144.
19. Kinon BJ, Noordsoy DL, Lu-Siefert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6 month comparison of olanzapine and quetiapine in patients with schizophrenia and schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006, 26:453-461. 10.1097/01.jcp.0000236658.16286.25, 16974184.
20. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: results of the 28-week, double-blind study in patients with schizophrenia. Am J Psychiatry 2005, 162:1879-1887. 10.1176/appi.ajp.162.10.1879, 16199834.
21. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17:407-418. 10.1097/00004714-199710000-00010, 9315992.
22. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, . HGGN Study Group One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006, 81:1-15. 10.1016/j.schres.2005.07.038, 16202565, HGGN Study Group.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
24. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl 1):S37-42. American Diabetes Association.
25. Canive JM. CATIE Study: Effectiveness among Ethnic/Racial Minorities. 2009, Presentation: Latin Behavioral Health Institute.
26. Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2005, 20:207-212. 10.1097/00004850-200507000-00003, 15933481.
27. Lieberman JL, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, . Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688, 16172203, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
28. Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, Niehaus DJ, Keyter N, Stein DJ. Ethnicity and treatment response in schizophrenia: comparisons of 3 ethnic groups. J Clin Psychiatry 2002, 63:9-14.
29. de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007, 27:22-27. 10.1097/JCP.0b013e31802e513a, 17224708.
30. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007, 191:23-29. 10.1192/bjp.bp.106.031716, 17602121.
31. Newcomer JW. Second-generation (atypicals) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
32. Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273-1276. 10.1176/appi.ajp.163.7.1273, 16816234.
33. Ananth J, Gunatilake S, Aquino S, Bach V, Costa J. Are African American patients at a higher risk for olanzapine-induced glucose intolerance?. Psychopharmacology (Berl) 2001, 157:324-325. 10.1007/s002130100862, 11605090.
34. Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res 2008, 48:1076-1085.
35. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry 2009, 70:318-325. 10.4088/JCP.08m04267, 19192469.
36. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res 2009, 110:95-102. 10.1016/j.schres.2009.02.006, 19269139.
37. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf 2008, 31:597-607. 10.2165/00002018-200831070-00005, 18558793.
38. Hodgkinson CA, Goldman D, Ducci F, DeRosse P, Caycedo DA, Newman ER, Kane JM, Roy A, Malhotra AK. The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology 2007, 32:190-196. 10.1038/sj.npp.1301177, 16936715.
39. Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C, Gaedigk A, Leeder JS, McEvoy JP, Weale ME, Goldstein DB. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008, 10:720-729. 10.1097/GIM.0b013e3181863239, 18813134.
40. Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophr Res 2008, 101:67-75. 10.1016/j.schres.2008.01.006, 2486404, 18262772.
41. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V, Straub RE, Weinberger DR, Kleinman JE. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 2008, 17:2293-2309. 10.1093/hmg/ddn130, 2465798, 18424448.
42. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009, 9:311-318. 10.1038/tpj.2009.24, 19451915.